Navigation Links
AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting
Date:10/1/2013

V Development Program
The AbbVie HCV clinical development program is intended to advance scientific knowledge by investigating an interferon-free, all-oral DAA regimen with the goal of producing high SVR rates in as many patients as possible, including those typically most difficult to cure. The large, multinational HCV program includes more than 2,200 patients from 30 countries.

AbbVie's hepatitis C portfolio includes investigational medicines with three different mechanisms of action targeting areas of the viral replication process including boosted protease inhibitor (ABT-450), polymerase (ABT-333) inhibitor and NS5A (ABT-267) inhibitor, currently being studied in clinical trials. ABT-450/r is co-formulated with ABT-267.

Details of AbbVie's phase III clinical programs are as follows: StudyPatients (n)Treatment RegimenTreatment DurationSAPPHIRE I

GT1, treatment-naïve

(600*)

ABT450/r +ABT267**

ABT333

Ribavirin

12 weeksSAPPHIRE II

GT1, treatment-experienced

(400*)

ABT450/r +ABT267**

ABT333

Ribavirin

12 weeksPEARL II

GT1b, treatment-experienced

(210*)

ABT450/r +ABT267**

ABT333

Ribavirin

12 weeks

SOURCE AbbVie Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
2. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
3. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
4. AbbVie Declares Quarterly Dividend
5. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
6. For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders Opinions Indicate that AbbVie/Eisais Humira Has the Best Clinical Profile Among Key Marketed Therapies
7. AbbVie to Participate in 2013 Jeffries Global Healthcare Conference
8. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
9. AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohns Disease
10. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
11. AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , Indien, August 1, 2014 ... BioQuiddity Inc. gaben heute bekannt, vor kurzem ... Anästhesieanwendungen zur Schmerzbehandlung nach chirurgischen Eingriffen eine ... Gebiet der Europäischen Union und weiterer europäischer ... versehene und mit Ropivacain gefüllte OneDose ReadyfusOR ...
(Date:7/31/2014)... MOUNTAIN VIEW, Calif., July 31, 2014 IRIDEX Corporation ... the second quarter and six months ended June 28, 2014.  ... quarter of 2014, up 15% from $9.2 million in the ... the first quarter of 2014. Revenues for the first six ... million in the first six months of last year. ...
(Date:7/31/2014)... July 31, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... developments for the quarter ended June 30, 2014. ... 30, 2014 Revenue Total revenue for the quarter ended ... for the quarter ended June 30, 2013 primarily due to ... Total revenue for the six months ended ...
Breaking Medicine Technology:Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 2Cipla und BioQuiddity geben EU-Geschäftspartnerschaft für OneDose-ReadyfusOR zur Schmerzbehandlung nach chirurgischen Eingriffen bekannt 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 2IRIDEX Reports 2014 Second Quarter, Six-Month Results 3IRIDEX Reports 2014 Second Quarter, Six-Month Results 4IRIDEX Reports 2014 Second Quarter, Six-Month Results 5IRIDEX Reports 2014 Second Quarter, Six-Month Results 6IRIDEX Reports 2014 Second Quarter, Six-Month Results 7Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28
... PHILADELPHIA, Jan. 5, 2011 ERT (Nasdaq: ... of technology and services to the pharmaceutical, biotechnology and ... Suicide Severity Rating Scale) solution facilitates compliance with the ... entitled "Suicidality: Prospective Assessment of Occurrence in Clinical Trials." ...
... Jan. 5, 2011 Cell Biosciences, Inc., a ... science researchers, today announced the launch of the ... imaging products, the FluorChem® M MultiFluor system. This ... fluorescent Western blots with key ease-of-use features aimed ...
Cached Medicine Technology:eC-SSRS Solution from ERT Facilitates Compliance with New FDA Guidance on Suicidality Assessment in Clinical Trials 2eC-SSRS Solution from ERT Facilitates Compliance with New FDA Guidance on Suicidality Assessment in Clinical Trials 3Cell Biosciences Launches New Platform for Multiplex Western Blot Detection 2
(Date:8/1/2014)... 2014 The evolving healthcare landscape ... pharmacies. At ThoughtSpot 2014, AmerisourceBergen and Good Neighbor ... and resources to enhance patient care and profitability. ... critical issues to give independent pharmacists the tools ... , ThoughtSpot show attendance experienced a nearly 70% ...
(Date:8/1/2014)... Washington, DC (PRWEB) August 01, 2014 ... Mike Thompson (D-CA), Gregg Harper (R-MS), and Peter ... H.R. 5380, the Medicare Telehealth Parity Act of ... "We fully support this effort to improve healthcare ... Linkous, chief executive officer of ATA. "These cost-saving ...
(Date:8/1/2014)... 2014 On Monday, June 30th, the ... Symposium in San Francisco, CA. Now in its fourth ... Marriott Union Square hotel. , “We are excited about ... speed with ACA compliance issues,” Quirk Healthcare Foundation Executive ... provides attendees guidance with NextGen implementation and use, electronic ...
(Date:8/1/2014)... 2014 (HealthDay News) -- Although many parents worry about their ... common choking hazard: food. Such was the case ... after eating a handful of nuts. "At the time, ... the coughing was related to his illness or choking," recalled ... A cashew had become lodged in his windpipe and had ...
(Date:8/1/2014)... August 01, 2014 Over the ... benefited from innovative technologies that have enabled cosmetic ... patient's tooth color. Moreover, the burgeoning elderly population ... age-related tooth ailments. Due to long-term use of ... individuals have demanded dental fillings, veneers and implants. ...
Breaking Medicine News(10 mins):Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2Health News:Food Is a Common Choking Hazard for Kids, Doctor Says 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... 10 Gen-Probe Incorporated,(Nasdaq: GPRO ) announced today ... results on Monday, April 28, 2008 at approximately,4:00 p.m. ... a,conference call at 4:30 p.m. ET. Henry L. Nordhoff, ... president, finance, and,chief financial officer, will host the call., ...
... provide more on ,how to, than ,how to prevent, ... study says that people surfing the Web for information about ... act rather than offering help and support. , Researchers from ... search terms, one at a time, into each of the ...
... Collaboration Platform is Gaining ... Significant Usage in the Healthcare Vertical, ... market,leader in delivering effective and easy-to-use Web 2.0 ... corporations and,membership organizations, is pleased to announce a ...
... Ensure Union Democracy, OAKLAND, Calif., April ... restore democracy to the nation,s largest union ... which will be,considered at the union,s upcoming ... proposed by members of United Healthcare,Workers-West, SEIU,s ...
... IRIDEX,Corporation (Nasdaq: IRIX ) today reported final financial results ... Revenue for the fourth quarter of 2007 was $14.1 ... fourth quarter of 2006. The,Company,s net loss was $15.8 million ... compared with a loss of $3.8 million or $0.48 per,diluted ...
... dramatically reduced with this method, researchers find , , ... fresh fruits and vegetables can reduce the risk ... all disease-causing bacteria, new research shows. , The ... reviewed by the U.S. Food and Drug Administration, ...
Cached Medicine News:Health News:Gen-Probe Announces Webcast of First Quarter 2008 Earnings Conference Call 2Health News:Suicide Data on Web Mostly Not Preventive 2Health News:Healthcare Sector Benefits from Online Community 2Health News:UHW Unveils Proposals for SEIU Convention 2Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 2Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 3Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 4Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 5Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 6Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 7Health News:IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results 8Health News:Irradiation Almost Erases Risk of Food Poisoning 2Health News:Irradiation Almost Erases Risk of Food Poisoning 3Health News:Irradiation Almost Erases Risk of Food Poisoning 4
... offers a complete line of flowmeters, available in oxygen, ... available in a variety of calibrations to best suit ... to the gas in use, the Amvex Flowmeter is ... the U with I. For Power Take-Off add PT ...
... Amvex offers a complete line of flowmeters, available in ... all available in a variety of calibrations to best ... specific to the gas in use, the Amvex Flowmeter ... replace the U with I. For Power Take-Off add ...
... complete line of flowmeters, available in oxygen, air, heliox ... a variety of calibrations to best suit your application. ... gas in use, the Amvex Flowmeter is a user ... with I. For Power Take-Off add PT to the ...
0-3.5 LPM Oxygen Flowmeter with Ohmeda male inlet...
Medicine Products: